STAT+

    Second death in Chinese clinical trial rekindles debate on safety

    Last year, a little-known Chinese startup took center stage at the American Society for Gene and Cell Therapy annual convention in New Orleans.  Speaking before a sprawling conference hall for the presidential symposium, HuidaGene CEO Alvin Luk presented data from one of the world’s first trials to test if CRISPR gene editing could treat children…

    Read More
    The Regulatory Review

    Lights, Camera, Deception | The Regulatory Review

    Scholars argue that regulators and celebrities must work to halt ads for miracle weight loss products. Celebrity endorsements draw heightened public attention. U.S. Senator Maggie Hassan (D-N.H.) questioned Mehmet Oz, a former television host and the administrator of the Centers for Medicare & Medicaid Services, about his advertisement of miracle weight loss products (MWLPs)—over-the-counter supplements…

    Read More
    Trump, Tylenol and the Plaintiffs Bar

    Trump, Tylenol and the Plaintiffs Bar

    We’ll admit we didn’t see this coming: President Trump advising pregnant women against using one of the most ubiquitous over-the-counter medicines in America. That’s what happened Monday when Mr. Trump joined his health advisers in linking acetaminophen, the main ingredient in Tylenol, to autism. What’s going on here has less to do with healthcare than…

    Read More
    China achieves invisibility tech breakthrough for early warning aircraft

    China achieves invisibility tech breakthrough for early warning aircraft

    Airborne early warning and control (AEW&C) aircraft – long considered indispensable yet vulnerable command nodes – have historically been high-value targets. Their powerful radar emissions, while essential for managing the battlespace, make them visible from hundreds of kilometres away. But the Chinese scientists said they found a way to make AEW&C signals exceptionally resistant to…

    Read More
    Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups

    Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups

    A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. “Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,” said Tony Ren, head…

    Read More